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Effects of recombinant human
erythropoietin on cognition and neural
activity in remitted patients with mood
disorders and first-degree relatives of
patients with psychiatric disorders: a study
protocol for a randomized controlled trial
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Hannelore Ehrenreich3,4, Gitte Moos Knudsen5,6, Lars Vedel Kessing1,6 and Kamilla Woznica Miskowiak1,2*
Abstract
Background: Bipolar disorder (BD) and unipolar disorder (UD) are associated with cognitive deficits and
abnormal neural activity in a “cognitive control network.” There is an increased prevalence of cognitive
dysfunction in psychiatric patients’ first-degree relatives, which constitutes a risk factor for psychiatric illness
onset. However, there is no treatment with enduring pro-cognitive efficacy. We found preliminary evidence
for beneficial effects of eight weekly doses of recombinant human erythropoietin (EPO) on cognition in BD
in a recent randomized controlled trial (RCT). The present RCT consists of two sub-studies that extend our
previous work by investigating important novel aspects: (1) the effects of 12 weekly doses of EPO on
cognition in first-degree relatives of patients with BD, UD, or schizophrenia; and (2) the effects of extending
the treatment schedule from 8 to 12 weeks in remitted patients with BD or UD; and (3) assessment of early
treatment-associated neural activity changes that may predict cognitive improvement.
(Continued on next page)
* Correspondence: kamilla.woznica.miskowiak@regionh.dk;
kamilla.miskowiak@regionh.dk
1Neurocognition and Emotion in Affective Disorder (NEAD) Group,
Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre
Copenhagen, Copenhagen University Hospital, Blegdamsvej 9, DK-2100
Copenhagen, Denmark
2Department of Psychology, University of Copenhagen, Øster Farimagsgade
2A, DK-1353 Copenhagen, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Petersen et al. Trials          (2018) 19:611 
https://doi.org/10.1186/s13063-018-2995-7
(Continued from previous page)
Methods: The trial comprises two parallel sub-studies with randomized, controlled, double-blinded, parallel
group designs. First-degree relatives (sub-study 1; n = 52) and partially or fully remitted patients with BD or
UD (sub-study 2; n = 52) with objectively verified cognitive dysfunction are randomized to receive weekly
high-dose EPO (40,000 IU/mL) or placebo (saline) infusions for 12 weeks. Assessments of cognition and mood
are conducted at baseline, after two weeks of treatment, after treatment completion, and at six-month follow-
up. Functional magnetic resonance imaging (fMRI) is conducted at baseline and after two weeks of treatment.
Psychosocial function is assessed at baseline, after treatment completion and six-month follow-up. The primary outcome
is change in a cognitive composite score of attention, verbal memory, and executive functions. Statistical power of ≥ 80%
is reached to detect a clinically relevant between-group difference by including 52 first-degree relatives and 52 patients
with BD or UD, respectively. Behavioral data are analyzed with an intention-to-treat approach using mixed models. fMRI
data are analyzed with the FMRIB Software Library.
Discussion: If this trial reveals pro-cognitive effects of EPO, this may influence future treatment of mood disorders and/or
preventive strategies in at-risk populations. The fMRI analyses may unravel key neurobiological targets for pro-cognitive
treatment.
Trial registration: ClinicalTrials.gov, NCT03315897. Registered on 20 October 2017.
Keywords: Bipolar disorder, Depression, Cognition, Cognitive dysfunction, Erythropoietin, Pro-cognitive efficacy, Prefrontal
cortex, Functional magnetic resonance imaging, Biomarker
Background
Cognitive deficits occur in moderate to severe degree in pa-
tients with bipolar disorder (BD) and unipolar disorder
(UD) [1–6]. These deficits are not only present during acute
episodes, but commonly persist after remission [1–7]. This
negatively affects patients’ quality of life, recovery rates, and
socio-occupational functioning [6, 8–12] of which reduced
work capacity is the largest area of socioeconomic burden
[13, 14]. A higher occurrence of mild to moderate deficits
has also been detected in BD, UD, and schizophrenia pa-
tients’ unaffected first-degree relatives compared with
healthy controls with no first-degree family history of psy-
chiatric disorder [15–19]. These impairments increase the
risk of psychiatric illness onset in these individuals [20].
Cognition is therefore a key treatment priority in patients
with mood disorders and genetically predisposed individ-
uals [21]. Nevertheless, there are no existing treatments
with solid and enduring efficacy on cognitive dysfunction in
these populations. New candidate treatments have only
produced disappointing or preliminary results [22]. This is
partially related to major methodological challenges, includ-
ing the absence of a sensitive brain-based biomarker model
to detect the efficacy of candidate treatments in phase 1
and 2 clinical trials [23]. In fact, candidate drug treatment
screening typically relies on animal models with com-
pounds being directly moved into large-scale, costly clinical
efficacy trials, in cases of beneficial effects in the animal
model. However, detection of pro-cognitive efficacy in ani-
mal models has poor predictive value in clinical trials [24],
which underlines the need for a more valid, sensitive bio-
marker model for pro-cognitive efficacy. Emerging evidence
highlights blood-oxygen-level dependent (BOLD) func-
tional magnetic resonance imaging (fMRI) response in the
prefrontal cortex (PFC) as a promising biomarker for cog-
nitive dysfunction and early cognitive improvement. In
particular, aberrant (primarily hypo-) activity in the dorso-
lateral and medial PFC (dlPFC and mPFC) during working
memory and episodic encoding tasks is the most reprodu-
cible neural marker of cognitive dysfunction across neuro-
psychiatric disorders, including BD, UD, schizophrenia,
and genetically predisposed individuals [25–31]. This ab-
errant activity reflects difficulties with selecting and main-
taining stimuli in working memory and strategic memory
encoding [32]. Reversal of aberrant dorsal prefrontal activ-
ity may therefore constitute a promising neural biomarker
for cognitive improvement.
Preclinical and clinical studies point to erythropoietin
(EPO) as one of the most promising candidate cognitive
enhancement treatments [33]. EPO is produced in the
brain where it exerts neurotrophic and neuroprotective
actions and plays a central role in cognitive functioning
[33–37]. Clinical studies have found that repeated sys-
tematically administered high-dose recombinant human
EPO versus placebo (saline) improves attention, mem-
ory, and executive functions after 8–12 weeks of treat-
ment across neuropsychiatric disorders, including
multiple sclerosis, Parkinson’s disease, schizophrenia,
treatment-resistant depression (TRD; defined as failure
to respond to ≥ 2 different types of antidepressant treat-
ments given in sufficient doses over sufficient time [38]),
and BD [39–43]. In particular, two randomized
placebo-controlled trials from our group revealed that
eight weekly EPO infusions improved several cognitive
domains in patients with BD and TRD [39, 40]. This was
accompanied by increased activity in dlPFC and dor-
somedial PFC (dmPFC) during working memory and
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episodic encoding tasks [44, 45]. Notably, a single dose
of EPO enhances cognition-related dlPFC and dmPFC
activity without producing any change in red blood cells
[46, 47]. This suggests that the EPO-associated increase
in task-related dorsal PFC (dPFC) reflects direct effects
of EPO in the brain. Taken together, these preliminary
findings point to EPO as a promising cognition treat-
ment and to neuronal activity change in the dPFC as a
key neural correlate of treatment-related improvement
of cognition. Nevertheless, our EPO trial had a number
of methodological limitations [39, 40]. First, cognitive
dysfunction was not verified with an objective (i.e.
neuropsychological) measure before enrollment of par-
ticipants. This is problematic since we found in post-hoc
analyses that objective cognitive impairment at baseline
was the strongest predictor of treatment success on cogni-
tion [48, 49]. Second, the primary outcome was a single
measure of verbal memory, which contrasts with the re-
cently published recommendations by the International
Society for Bipolar Disorders (ISBD) Targeting Cognition
Task Force that the primary outcome in cognition trials
should be a broad cognitive composite score spanning at-
tention, memory, and executive function [50]. Third, the
lack of long-term follow-up assessment hampered insight
into whether treatment-associated cognitive improvement
was long-lasting. Fourth, we had not assessed functional
capacity in the patient sample and thus had no insight into
whether the EPO-related improvement of cognition trans-
lated into better functional capacity.
Aims and hypotheses
The aims of the present EPO trial are threefold. First, we
aim to investigate whether 12 weekly recombinant hu-
man EPO infusions ameliorate cognitive impairments in
first-degree relatives without psychotic or mood disor-
ders to patients with BD, recurrent UD, or schizophrenia
(sub-study 1). This will allow for the first time to judge
the disease-independent response of inherent cognitive
genetic traits. Second, we will examine whether a longer
treatment period is associated with similar or stronger
cognitive improvement in remitted patients with BD or
recurrent UD (defined as ≥ 2 treatment-requiring de-
pressive episodes) (sub-study 2). Third, we will explore
with fMRI the early neuronal changes that are predictive
of subsequent clinically relevant cognitive improvement
across these groups. We hypothesize that:
1. 12 weekly EPO infusions improve cognition in first-
degree relatives and remitted patients with BD or
recurrent UD in comparison with saline.
2. EPO versus saline-treated participants will display
early cognition-related neural activity in dorsal PFC
in the direction of the activity in healthy controls,
which will correlate with cognitive improvement.
Methods and design
Participants
We will recruit 52–58 first-degree relatives without
psychotic or mood disorders to patients with BD, recur-
rent UD, or schizophrenia (sub-study 1) and 52–58 pa-
tients with BD or recurrent UD in partial or full
remission (defined as a score of ≤ 14 on the Hamilton
Depression Rating Scale 17-items (HDRS-17; [51]) and
the Young Mania Rating Scale (YMRS; [52]) (sub-study
2) with objectively verified cognitive dysfunction to ob-
tain a complete dataset for 52 participants per sub-study
(assuming a 10% drop-out rate from inclusion to treat-
ment completion). Participants will be recruited from
psychiatric centers in The Mental Health Services in the
Capital Region of Denmark, consultant psychiatrists in
the Capital Region of Denmark, as well as through ad-
vertisements on relevant websites. Within each
sub-study, half of the participants will be randomized to
receive active treatment (n = 26–29), while the other half
will receive placebo (n = 26–29).
Eligible participants are aged 18–65 years, have fluent
Danish skills, and display objectively verified cognitive
dysfunction according to the Screen for Cognitive Im-
pairment in Psychiatry (SCIP) [53–55]. Specifically, par-
ticipants must have a total SCIP score of ≤ 77, which
provides adequate sensitivity and specificity for cognitive
impairment (86% and 70%, respectively) [53], or have a
score corresponding to ≥ 1 standard deviation (SD)
below the norm on ≥ 2 SCIP subtests [50, 53]. For indi-
viduals with a verbal IQ ≥ 120 (i.e. ≥ 1 SD higher than
the average IQ in age-matched healthy control partici-
pants) according to the Danish Adult Reading Test
(DART [56]), the adjusted inclusion criterion is a score >
1 SD below the norm on ≥ 1 SCIP subtest. In this way,
cognitive impairment is to some degree established with
reference to participants’ premorbid IQ in accordance
with recent guidelines by the ISBD Targeting Cognition
Task Force [50].
Patients are eligible if an ICD-10 diagnosis of BD or
recurrent UD is confirmed with the Schedules for Clin-
ical Assessment in Neuropsychiatry (SCAN) [57]. The
maximum daily use of benzodiazepines allowed is
22.5 mg oxazepam (benzodiazepines will be avoided on
the day of neuropsychological assessments). Patients’
medication must remain unchanged during the study
period, unless a change of medication is deemed neces-
sary by their treating psychiatrist. First-degree relatives
are allowed to have minor psychiatric disorders (defined
as ICD-10 codes > F40), since these individuals are at
particular risk of (major) psychiatric illness onset. Specif-
ically, first-degree relatives are eligible even if diagnosed
with a psychiatric disorder categorized within the
ICD-10 as F40–49 (anxiety, dissociative, stress-related,
somatoform, and other non-psychotic mental disorders),
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F50–59 (behavioral syndromes associated with physio-
logical disturbances and physical factors), and F60–69
(disorders of adult personality and behavior) codes, as
long as these disorders only influence their current state
to a minor degree (i.e. they are well-treated at the time
of inclusion).
Exclusion criteria for both sub-studies are individuals
with intellectual disability (defined as an estimated IQ <
70) [50], schizophrenia or schizoaffective disorder,
neurological disorder (including dementia), current alcohol
or substance abuse (up to 3 months prior to inclusion), or
history of head trauma. To ensure safety of EPO treatment
throughout the study, candidates are also excluded if they
have significant medical conditions (e.g. heart disease, dia-
betes, renal failure, untreated/insufficiently treated hyper-
tension, malignancies, and/or thromboses), personal or
first-degree family history of epilepsy or thromboembolic
events, have received electroconvulsive therapy (ECT)
three months before participation, are dyslexic, use
contraceptive medications, smoke, are pregnant, or are
breastfeeding. Regarding fMRI assessments, participants
are not eligible if they suffer from claustrophobia or have
a pacemaker and/or other metal implants inside their bod-
ies. Participants, who do not meet these fMRI inclusion
criteria will not be excluded from the trial per se, but only
from the two fMRI assessments.
These criteria are similar to the procedures in our
previous studies [39, 40, 58]. To ensure that partici-
pants receive a sufficient concentration of EPO, can-
didates are excluded if they weigh < 45 or > 95 kg or
are overweight (BMI > 30). Participants must be able
to provide written informed consent to be included in
the study. These procedures are in accordance with
the ethical standards of the Danish Research Ethics
Committee for the Capital Region of Denmark (proto-
col number H-16043370) and The Danish Data Pro-
tection Agency Capital Region of Denmark (protocol
number RHP-2017-020). See Additional file 1 (SPIRIT
2013 Checklist) for a trial protocol checklist.
Setting
Participants will receive intravenous infusions of either
recombinant human EPO (Epoetin alpha; Eprex;
40,000 IU/mL) or placebo (1 mL NaCl) diluted with
100 mL saline (0.9% NaCl) administered for 15 min once a
week (7 ± 2 days) during a 12-week study period at the
Copenhagen Affective Disorder Research Center (CADIC),
Psychiatric Centre Copenhagen, Rigshospitalet. The EPO
doses are similar to those found to be effective for modu-
lating neural and cognitive function with short-term ad-
ministration [46] and for enhancing cognition with
long-term treatment [39, 40, 42, 59]. Outcome assessments
are also carried out at Psychiatric Centre Copenhagen and
Neurobiology Research Unit (NRU), Rigshospitalet.
Study design and procedures
The trial has a randomized, double-blinded, placebo-
controlled, parallel group design. The study design com-
prises four major assessments (baseline, week 3, week
13, and a six-month follow-up after treatment comple-
tion) and weekly safety monitoring and study medication
infusions during the 12-week treatment period. Partici-
pants will be informed about the study and given a par-
ticipant information sheet. Before undergoing eligibility
assessments, participants provide written informed
consent, which will be obtained by one of the named
authors.
The baseline assessment is divided into two days, 1–
3 days apart for practical reasons and to avoid attrition.
On the first day of the baseline assessment, participants
are mood rated with the HDRS-17 and YMRS to ensure
remission and afterwards complete an fMRI scan at
Copenhagen University Hospital, Rigshospitalet. On the
second baseline day, participants attend Psychiatric Centre
Copenhagen for a fasting research blood test (peripheral
biomarker measure) followed by an assessment of cogni-
tive functions with a neuropsychological test battery, ver-
bal IQ (assessed with the Danish Adult Reading Test;
DART [56]), and filling in questionnaires concerning sub-
jective cognitive complaints, quality of life, level of func-
tioning, and functional capacity, as well as depression and
mania symptom severity ratings. Functional capacity will
be assessed using a clinician-rated interview and a
performance-based task. Mood ratings are performed with
the HDRS-17 [51] and the YMRS [52]. After two weeks of
treatment (i.e. two doses of EPO or saline), fMRI scan, re-
search blood samples, neuropsychological testing, mood
ratings, and questionnaires on subjective cognitive diffi-
culties are repeated. After treatment completion (week 13)
and at the six-month follow-up, the neuropsychological
tests, questionnaires concerning subjective cognitive com-
plaints, quality of life, and functional capacity (self-re-
ported and performance-based) are repeated. Research
blood samples are collected in week 13, but not at the
six-month follow-up. Sleep quantity and quality in the
past three days is assessed before each of the four major
assessment time points and with online self-rating using
the Pittsburgh Sleep Quality Inventory (PSQI) [60] asses-
sing sleep quality one week before the baseline, week 3,
week 13, and the six-month follow-up assessment. Blood
samples are collected at baseline and weeks 3 and 13 for
assessment of potential blood-based biomarkers of
pro-cognitive effects. An intermediate mood symptom rat-
ing for patients (sub-study 2) is performed at week 7 to as-
sess whether they are in (partial) remission throughout
the study period. To ensure safety, we conduct weekly
monitoring, comprising thorough medical examinations
and blood test evaluations, for the duration of the treat-
ment course and in weeks 13 and 15. Pregnancy tests are
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mandatory for and will be performed on fertile female par-
ticipants before the first study medication infusions and
every second week during the active treatment period.
Blood screening and thorough medical examinations are
undertaken at baseline, weekly throughout the 12-week
treatment period as well as one and three weeks after
treatment completion to continuously monitor red blood
cell levels and ensure participant safety.
EPO will be kept at 2–8 °C during transport and stor-
age to reduce the risk of damaging the medication and
potential related adverse side effects. EPO will be dis-
solved in 100 mL saline and infusions will be given
intravenously over 15 min to reduce the possibility of
acute allergic reactions. If blood test analyses reveal sig-
nificantly increased hematocrit (men: > 50%; women: >
48%) at two consecutive measurements within the same
week, bloodletting (450 mL) will be performed on a
weekly basis with no cessation of treatment before
hematocrit values are normalized. Patients are therefore
asked to regularly drink plenty of water to avoid “pseu-
do”-increases in hematocrit. In cases of significant in-
crease in thrombocytes (> 400 billion/L) or drop in
reticulocytes (ERC(B) < 1 × 10− 3), two repeated controls
will be performed in the following week. If thrombocyte
and/or reticulocyte values remain abnormal, participants
will be withdrawn from further study participation and
monitored with weekly medical examinations and blood
samples until values are stabilized. If necessary, these
participants will be hospitalized for observation. Lists of
any pseudo-anonymized outcome data collected for par-
ticipants who discontinue or deviate from further study
participation will be kept in a locked cabinet.
Randomization and blinding
The independent Pharma Consulting Group AB
(www.pharmaconsultinggroup.com) has conducted block
randomization for each sub-study group. Randomization
is performed utilizing a 1:1 allocation ratio. Treatment
groups will be stratified for gender and age (sub-study 1:
< or > 30 years; sub-study 2: < or > 35 years). At the time
of enrolment, diagnosis, gender, and date of birth are
registered in order to determine the appropriate stratum
to which the participant belongs. Study identification
numbers will be given consecutively within each
stratum. To ensure blinding of outcome-assessors,
sealed randomization envelopes are kept in a locked cab-
inet only accessible to study personnel responsible for
preparing the study medication, who are not involved in
evaluation of the efficacy parameters or regular inter-
action with participants (i.e. the study nurse and PhD
student). Double-blinding is achieved during infusion
through injection of 1 mL colorless recombinant human
EPO (Eprex; 40,000 IU; Janssen-Cilag) or saline (NaCl
0.9%) is injected into a standard 100 mL saline (NaCl
0.9%) infusion bag that will be given to the blinded re-
search nurse or physician administering the study medi-
cation within 1 h before drug administration. The
weekly safety monitoring of blood tests and side effects
will be completed by medical doctors not involved in
outcome assessments. To maintain blinding, participants
are instructed to not talk about any symptoms or poten-
tial physical side effects associated with high-dose EPO
treatment (e.g. increased hematocrit or bloodletting)
with the study personnel who administer infusions or
are involved in outcome assessments. At the last
follow-up assessment (after six months), participants
and blinded study personnel are asked to guess whether
they believe they received EPO or saline treatment dur-
ing their study participation. This is done to evaluate al-
location concealment. Unblinding is permissible for
safety reasons in cases of side-effects or serious adverse
events likely or directly related to the study medication.
The procedure for revealing a participant’s allocated
intervention during the trial involves opening his or her
randomization envelope. In these cases, it is LSS, MV, or
LVK’s sovereign decision, whether the randomization
code should be broken. The study is monitored by the
Good Clinical Practice Unit (GCP) at the Copenhagen
University Hospital (www.gcp-enhed.dk/kbh).
Outcome assessments
For an overview of outcome assessment frequency and
timing, see Fig. 1. The outcome measures listed below
are consistent with the latest recommendations from the
ISBD Task Force [50] suggesting the inclusion of a cog-
nitive composite score as the primary outcome measure,
a single intervention-specific cognitive measure as the
secondary outcome, and multiple individual cognitive
measures as tertiary (i.e. exploratory) outcome measures.
Primary outcome measures
The primary outcome measure is a cognitive composite
score, consisting of neuropsychological tests covering at-
tention, memory, and executive functions. We have pre-
viously demonstrated an improvement on this “speed of
complex cognitive processing” composite measure in pa-
tients with BD after eight weeks of EPO treatment [39].
In the present trial, the specific tests included in the pri-
mary composite outcome measure are the Rey Auditory
Verbal Learning Test (RAVLT) [61, 62], The Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS) Coding [63], Verbal Fluency with the letter “D”
[64], Wechsler Adult Intelligence Scale (WAIS)-III
Letter-Number Sequencing [65], Trail Making Test Part
B (TMT-B) [66], and Rapid Visual Information Process-
ing (RVP) from the Cambridge Neuropsychological Test
Automated Battery (CANTAB, Cambridge Cognition
Ltd.). To derive the cognitive composite score, we will
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Fig. 1 (See legend on next page.)
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z-transform and sum performance scores from RAVLT
total recall, TMT-B, WAIS-III Letter-Number Sequen-
cing, RBANS Coding, Verbal Fluency (letter “D”), and
RVP speed for correct responses using the mean and SD
from a healthy control group.
Secondary outcome measure
The secondary cognitive outcome measure consists of
the RVP (CANTAB), which revealed particularly strong
effects of EPO in our previous eight-week study [39],
and a functional capacity outcome measure assessed
with the clinician-rated interview Functional Assessment
Short Test (FAST) [67].
Tertiary outcome measures
The tertiary cognitive outcome measure comprises the
RAVLT, RBANS Coding and Digit Span, Verbal Fluency
with the letters “S” and “D” [64], WAIS-III Letter-Number
Sequencing, the One Touch Stockings of Cambridge
(OTS; CANTAB), the Spatial Working Memory (SWM;
CANTAB), as well as the TMT-B and Trail Making Test
Part A (TMT-A) [66]. The tertiary level of psychosocial
functioning outcome are the following questionnaires and
performance-based task: Assessment of Quality of Life
(AQoL) [68], the Cognitive Complaints in Bipolar Dis-
order Rating Assessment (COBRA) [69], Sheehan Disabil-
ity Scale (SDS) [70], the UCSD Performance-Based Skills
Assessment-B (UPSA-B) [71, 72], the World Health
Organization Quality of Life (WHOQOL-BREF) [73], and
the Work and Social Adjustment Scale (WSAS) [74]. His-
tory of early life stress will be assessed with the Childhood
Abuse and Trauma Scale [75] at the time of inclusion.
To minimize learning effects on neuropsychological
test performance at the follow-up assessments, alternate
versions of the RAVLT (original list AB, GeAB, and
Cr-AB) and RBANS Coding and Digit Span (version A
and B) [61–63] are used. These versions will be adminis-
tered in counter-balanced order within each stratum.
Neural biomarkers of potential pro-cognitive effects
To assess whether an early change in neural activity in
the dlPFC and mPFC is predictive of pro-cognitive effi-
cacy, participants will complete MRI scan at baseline
and following two weeks of treatment. The MRI scan
duration is approximately 1.5 h and includes a structural
scan, three functional tasks, including (1) a Strategic
Picture Encoding Task, (2) a Verbal task, and (3) a
Spatial N-back working memory task from our previous
study [45], as well as a checkerboard pattern sequence
and a resting state sequence. The fMRI protocol has
been constructed to evaluate the sensitivity and specifi-
city of potential neural activity change in the dlPFC and
mPFC after two weeks of active treatment and whether
this can predict cognitive improvement after 12 weeks
of treatment.
Exploratory measures of potential pro-cognitive effects
To further increase insight into the underlying neurobio-
logical mechanisms involved in the potential beneficial cog-
nitive effects of EPO, blood samples from baseline, week 3,
and after treatment will be analyzed for the exploratory
purpose of investigating whether baseline levels and/or
changes of peripheral biomarkers, including inflammatory
markers, brain-derived neurotrophic factor (BDNF), and
metabolic parameters (fat and glucose markers), are corre-
lated with cognitive improvement [76–83]. Baseline blood
samples will also be used for assessment of potential influ-
ence of Catechol-O-methyltransferase (COMT: Val158-
Met), BDNF: Val66Met, and EPO and EPO-R genotypes on
the treatment-related change in cognition and neural
activity.
We will perform post-hoc exploratory analyses investi-
gating which demographic, clinical, cognitive, and neural
variables at baseline predict treatment efficacy on the
primary cognitive outcome measure, since there is a
paucity of research into which baseline factors are asso-
ciated with cognitive improvements [84].
Biochemistry
Research blood samples will be transferred to the
Neuropsychiatric Laboratory, Rigshospitalet, and stored
at − 80 °C until use. Measurements will be performed at
Neuropsychiatric Laboratory, Department O, and at De-
partment of Clinical Pharmacology, Rigshospitalet.
Statistical analyses
The threshold for statistical significance is considered p
< 0.05 (two-tailed). For significant results regarding the
primary, secondary, and tertiary measures, relevant ef-
fect sizes will be reported in addition to the p values. All
(See figure on previous page.)
Fig. 1 Schedule of enrolment, interventions, and assessments. EPO erythropoietin, RVP Rapid Visual Information Processing (CANTAB, Cambridge
Cognition Ltd.), FAST Functional Assessment Short Test, RAVLT Rey Auditory Verbal Learning Test, RBANS Repeatable Battery for the Assessment
of Neuropsychological Status, WAIS-III LNS Wechsler Adult Intelligence Scale Version III Letter-Number Sequencing, OTS One Touch Stockings of
Cambridge, SWM Spatial Working Memory, TMT-A Trail Making Test Part A, TMT-B Trail Making Test Part B, AQoL Assessment of Quality of Life,
COBRA Cognitive Complaints in Bipolar disorder Rating Assessment, SDS Sheehan Disability Scale, UPSA-B UCSD Performance-Based Skills
Assessment-B, WHOQOL-BREF World Health Organization Quality of Life, WSAS Work and Social Adjustment Scale, DART Danish Adult Reading
Test, CTQ Childhood Trauma Questionnaire, SCIP Screen for Cognitive Impairment in Psychiatry (Danish version)
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statistical analyses are performed using the Statistical
Package for Social Sciences (SPSS, version 23, IBM Cor-
poration, Armonk, NY, USA).
Primary, secondary, and tertiary outcome measure analyses
Behavioral data from neuropsychological test score per-
formance, subjective cognitive impairments, quality of
life, level of functioning, psychosocial functioning, and
mood symptoms (i.e. data from the primary, secondary,
and tertiary outcomes) will be analyzed using mixed
models design and intention-to-treat (ITT) analyses in
cases of missing data. Data will be analyzed for every
participant with any assessment. No interim analyses will
be performed.
Functional MRI analyses
Functional MRI data are pre-processed and analyzed
with FMRIB Expert Analysis Tool (FEAT) and the
“randomize” algorithm implemented in FSL (FMRIB
Software Library; www.fmrib.ox.ac.uk/fsl). We will assess
whether early differences between EPO and placebo
groups in task-related neural activity during each of the
three fMRI paradigms after two weeks of treatment (ad-
justed for baseline activity) predict subsequent treatment
efficacy on cognition at treatment completion. Neuro-
psychological test performance and fMRI data from 40
cognitively intact healthy controls without personal or
first-degree relative history of mental illness from the
BIO study [85] is used as external normative data.
Region of interest (ROI) analyses of fMRI data from
the N-back working memory tasks will be carried out to
investigate the effects of EPO on neural activity in
dlPFC. The difference in neural activity between the
EPO and saline groups in week 3 will be investigated by
extracting and analyzing mean percent signal change in
dlPFC adjusted for potential differences in baseline activ-
ity using univariate analysis of covariance (ANCOVA)
and with whole-brain analyses (FEAT) in week 3 (with
adjustment for potential activity differences at baseline).
We will also investigate the hypothesized early dorsal
PFC activity change in response to EPO versus saline
with volume of interest (VOI) for the dorsal PFC. Volume
of interest analyses of dorsal PFC and the hippocampus
are conducted to assess fMRI data from the Strategic Pic-
ture Encoding Task. Finally, exploratory whole-brain ana-
lyses are conducted to assess treatment-related activity
change in other brain regions. Differences in neural activ-
ity between groups will be correlated with potential
change in the primary cognitive composite score at week
3 and after treatment completion. If this correlation is sig-
nificant, multiple regression analyses will be performed
with adjustment for mood symptoms, age, and gender to
assess the potential predictive value of early neural activity
change for potential pro-cognitive efficacy after 12 weeks
of EPO treatment.
Peripheral blood-based biomarker analyses
Post-hoc analyses will be conducted on research blood
sample data collected at baseline, week 3, and week 13
for the exploratory purposes to assess whether potential
efficacy on cognition in response to EPO versus saline is
accompanied by and related to changes in blood-based
biomarkers of inflammation and metabolism.
Sample size and power calculation
Sample size and statistical power has been calculated by
PharmaConsulting Group AB with Statistical Analysis
Software (SAS), based on our previous findings assessing
cognitive effects of weekly infused EPO [48]. The differ-
ence in cognitive change between the EPO and the
saline-treated groups from baseline to after treatment
was 0.5 SD [48]. In this trial, we estimate a clinically
relevant differential change in the primary cognitive
composite score between the EPO and placebo groups
from baseline to week 13 (treatment completion) to be
at least 0.4 SD (corresponding to a moderate effect size)
with a SD of the mean change of 0.5 between these
groups. This is consistent with the recommendations
listed by the ISBD Cognition Task Force [50]. Specific-
ally, the task force indicated that a differential change
between groups of 0.2–0.4 SD on a global composite
score reflects a potentially clinically relevant change,
since this may translate into moderate–large functional
improvement in patients with mood disorders [50]. In
our eight-week EPO trial, the difference regarding
change in the cognitive composite score from baseline
to treatment completion was 0.5 SD between the EPO
and the saline groups [48]. Based on the ISBD task force
recommendations and our earlier findings regarding ef-
fects of longer-term EPO treatment, we estimate that a
sample size of N = 104 (i.e. n = 52 participants within each
sub-study with n = 26 in each treatment group) will reach
a ≥ 80% power for detecting a similar clinically relevant
differential change of 0.4 SD in the primary cognitive
composite outcome measure with a SD of this change of
0.5 between the treatment groups at an alpha level of 5%
(two-sided test). Based on our assumption of a 10%
drop-out rate from baseline to treatment completion, we
plan to recruit up to n = 58 for each sub-study to achieve
complete datasets for n = 52 participants per sub-study
(first-degree relatives and patients, respectively).
Data management and monitoring
All personal information will be obtained at the eligibil-
ity assessment or from patient records, if patients are
unable to provide the necessary pieces of information.
Written informed consent forms will be kept in a locked
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filing cabinet, while a password-protected list that
matches participant ID numbers with personal informa-
tion will be stored separate from pseudo-anonymized
data. The list matching participants’ personal informa-
tion with their ID number will be deleted and consent
forms maculated 10 years after study completion. At this
point, all data will be completely anonymized. All trial
authors will have access to the final trial dataset.
Pseudo-anonymized research data will be registered in
the Research Electronic Data Capture (REDCap) data-
base, which fulfills the Danish data law to keep research
participants’ records and meets GCP requirements for
data management. Study personnel involved in outcome
assessments and evaluation of these outcomes are
blinded to study medication until the data analyses are
completed. Consequently, blood sample results and lists
of potential adverse effects are registered in The Health-
care Platform (Sundhedsplatformen) to which only med-
ical doctors responsible for participant safety and the
person involved in blinding of the study medication have
access. REDCap has a logging module, which enables
tracking of the data entered. Data quality is ensured by
verification of data entered by outcome assessors and
score range restrictions on values from neuropsycho-
logical test and questionnaire results. All neuropsycho-
logical data for the primary outcome measure will be
double-checked by JZP.
Participant retention
All participants are offered feedback on the changes of
their neuropsychological performance across assessment
time points once they have completed the six-month
follow-up assessment. Furthermore, employed partici-
pants will be given a compensation of 100 DKK per hour
for 10 h of neuropsychological and fMRI assessments.
Travel expenses with public or private transportation are
reimbursed for all participants. Finally, patients will
benefit from the extra care they receive from study




Cognitive dysfunction is a core feature of BD and UD,
which reduces socio-occupational functioning. The lack
of clinically available treatments with pro-cognitive effi-
cacy is partially related to major methodological chal-
lenges in this relatively new field, including the absence
of a sensitive brain-based biomarker model to select
among candidate treatments. Preclinical and clinical
studies point to EPO as one of the most promising can-
didate cognitive enhancement treatments, making it a
suitable potential treatment for assessment of neural ac-
tivity change associated with improvement of cognition.
The aim of the present trial is therefore twofold: (1) to
clarify whether 12 weekly EPO versus placebo (saline)
treatment has pro-cognitive effects in cognitively impaired
remitted patients with BD or recurrent UD and
first-degree relatives without mood or psychotic disorders
to patients with BD, recurrent UD, or schizophrenia; and
(2) to identify patterns of early treatment-related neural
activity change that may be predictive of subsequent cog-
nitive improvement.
Strengths
The present EPO trial includes, for the first time,
first-degree relatives with cognitive impairment (sub-study
1), which will clarify whether EPO has the potential to im-
prove cognitive and functional outcome in genetically pre-
disposed individuals, who are at increased risk of stress
and illness onset [86]. In general, the present trial (both
sub-studies) has several advantages over our previous
EPO cognition trial in BD and TRD [39, 40]. Notably, the
previous trial did not involve pre-screening for objectively
verified cognitive dysfunction, which may have introduced
type II errors since 30–50% of bipolar patients and 60–
80% of depressed patients are relatively cognitively intact
compared with neuropsychological test norms for
age-matched individuals, despite frequent subjective cog-
nitive complaints [1, 2, 87]. In the present trial, we will
therefore only include participants who present objective
cognitive dysfunction on a brief cognition screening tool
(SCIP) in keeping with the recent methodological recom-
mendations by the ISBD Targeting Cognition Task Force
[50]. Due to the cognitive heterogeneity characterizing re-
mitted patients with BD and UD [87], the ISBD Cognition
Task Force recommends a broad cognitive composite
score spanning attention, memory, and executive function
as primary outcome in cognition trials in mood disorders
[50]. In keeping with this, we have chosen the “speed of
complex cognitive processing” composite as the primary
outcome. While the longest follow-up in our previous
EPO trial was only six weeks after treatment completion,
we here include a six-month follow-up assessment to
assess whether any treatment-related cognitive improve-
ments persist long term. Further, the inclusion of
self-reported, observer-rated, and performance-based
measures of functional capacity will provide insight into
whether potential cognitive benefits of EPO translate into
improved daily functioning, which is the ultimate goal for
our patients. Finally, it is likely that the present expansion
of the treatment period from 8 to 12 weeks will result in
more robust and longer-lasting effects of EPO treatment.
Beyond EPO, the use of fMRI to assess early treatment-re-
lated change in neuronal activity within regions of the
“cognitive control network” and the correlation between
such change and subsequent cognitive improvement will
provide insight into the neurobiological targets of
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potential cognitive improvement and thus aid future treat-
ment development strategies [50, 88].
Limitations
The disadvantage of only enrolling participants with ob-
jectively verified cognitive dysfunction is that this limits
recruitment, since many patients with mood disorders
are relatively cognitively intact in comparison with
norms [1–3, 87]. For these reasons, we selected a cut-off
on the brief cognition screening tool (SCIP) to ensure
the presence of minimum subtle cognitive impairments
in this trial. Due to the extensive somatic co-morbidity
exclusion criteria, the study sample may not represent
the full range of BD and recurrent UD, which limits
generalizability of findings. However, this is necessary to
ensure participant safety, which is of principal import-
ance in the trial. Notwithstanding, this highlights the
major limitation of this treatment, since a large propor-
tion of patients have somatic co-morbidities and EPO
may therefore only become relevant for treatment of
cognitive impairments in a subgroup of patients (if the
study finds positive effects). This highlights a need for
development of other kinds of treatments to improve
cognition such as action-based cognitive remediation
(ABCR) [89]. The thorough assessments before and dur-
ing study participation may contribute to a selection of
participants who are more positive towards clinical re-
search and therefore also more willing to cooperate. In-
deed, this may partially explain the very high compliance
in our previous EPO trial, in which there was only one
drop-out [39]. Finally, patients with BD and recurrent
UD will be on medication for ethical reasons and to aid
generalizability of the results [50]. However, this con-
comitant pharmacological treatment may confound
neuropsychological test and fMRI task data due to pos-
sible effects of medications on cognition and BOLD re-
sponse [90]. We therefore seek to minimize confounding
effects by avoiding changes in patients’ concomitant
medication during the study period, if possible, and by
carefully recording their medication, so potential inter-
action effects with EPO can be assessed in post-hoc ana-
lyses. Further, we anticipate an equal distribution of
medications between treatment groups as in our previ-
ous EPO studies [39, 40], so any differences in cognition
and neural change between groups will be due to EPO
or saline.
Study feasibility
We have previously conducted a double-blinded ran-
domized trial of eight weeks of EPO treatment in 84 pa-
tients with mood disorders at the Psychiatric Centre
Copenhagen, Rigshospitalet. Based on this trial as well
as our collaboration on recruitment with other psychi-
atric centers and consultant psychiatrists in the Capital
Region of Denmark, we consider recruitment of 52–58
patients and 52–58 first-degree relatives over 30 months
to be feasible.
Safety procedures and monitoring of EPO infusions
EPO is a common treatment option for anemia patients
and has a good safety profile when carefully monitored.
However, hematopoietic effects of repeated EPO admin-
istration are associated with risk of hypertension and
blood clotting [91]. Indeed, EPO has been associated
with increased mortality in severely ill stroke patients
with previous thromboembolic disease, including pa-
tients given thrombolytic treatment [92, 93]. To ensure
participant safety in this trial, we therefore implement
extensive exclusion criteria to exclude candidates at in-
creased risk of thromboembolic events. Extremely rare
but serious side effects associated with long-term EPO
administration in patients with chronic severe somatic
diseases are thromboses at the site of dialysis in patients
with kidney failure, seizure, and potential tumor growth
[94]. The rare condition, pure red cell aplasia (PRCA),
has been detected with subcutaneous infusions and poor
packaging of the EPO medication. However, its inci-
dence rate has fallen to 0.3/100,000 patient years [95–
97]. Reticulocyte counts constitute the first indicator of
PRCA and are therefore thoroughly monitored. We ob-
served no serious adverse events in eight weeks of
weekly EPO infusions in the proposed dose and adminis-
tration form in our previous studies of 84 patients with
TRD or BD [39, 40]. EPO-related hematocrit levels in-
creased to an extent that necessitated blood-letting in
five (14%) of the 35 EPO-treated patients in weeks 3–8
(with one in week 3). This corresponds to observations
by Ehrenreich et al. [41, 42]. We discontinued EPO
treatment in six patients (17%) after 5–7 weeks due to
thrombocyte level increase (these participants completed
all assessments). Participant safety monitoring therefore
involves thorough medical examinations, systolic and dia-
stolic blood pressure measurement, blood sampling, elec-
trocardiography (ECG), and additional safety parameters
at baseline, weekly during the study, and at three weeks
after EPO/placebo treatment completion. Due to careful
adherence to the exclusion criteria and weekly safety mon-
itoring, we evaluate the risk of such side effects and ad-
verse events of EPO treatment to be extremely low in this
trial. Further, participants will be informed of all potential
adverse effects before randomization and are instructed
that iron supplements (which increase hematocrit levels)
are prohibited during the active treatment period. Al-
though the risk of potential thrombosis or suspected
PRCA is low, included participants are given a pocketsize
plastic card with instructions about what to do and con-
tact details to medical doctors at the local emergency de-
partment in case these symptoms appear. Participants stay
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at the clinic for observation for at least 30 min after each
infusion for a research nurse to monitor potential acute
side effects of EPO (e.g. rash at the infusion site or
headache).
Ethical considerations
We evaluate the risks and disadvantages of participating
in the study to be minimal based on previous EPO trials
[39, 40] and the described precautions, exclusion cri-
teria, and carefully established treatment plan in case of
side effects.
Although patients are not required to withdraw from
their usual antidepressant or mood stabilizing medica-
tion, they are requested not to change their doses or
treatment during the study course. This may give rise to
ethical considerations for the included remitted patients,
albeit we show consideration for their safety, rights, and
wellbeing by excluding those who are required to change
the type or dose of their mood stabilizing medical treat-
ment by their psychiatrist. In case of significant symp-
tom worsening, patients’ clinical needs, integrity, and
autonomy come before the scientific interests of the
study. Because of the lack of effective treatments target-
ing cognitive dysfunction in mood disorders [22, 98], the
use of a placebo group is necessary for investigating
potential beneficial cognitive effects of EPO. We are un-
able to offer active EPO treatment to these participants
after trial completion given the only preliminary evi-
dence for efficacy of EPO on cognition. This is likely to
be disappointing for the 50% of participants random-
ized to saline. The duration of neuropsychological test
assessments and mood ratings may lead to attrition in
some participants. However, we keep the duration of
neuropsychological assessments and fMRI scans to a
minimum to avoid attrition and reduce the risk of
drop-out. Albeit the procedure is safe and non-invasive,
some participants may experience it as claustrophobic
and anxiety provoking. For these reasons, we exclude
people, who suffer from claustrophobia from fMRI as-
sessments. Blood sampling may be associated with
slight discomfort but is routine hospital care. Partici-
pants will benefit from the extra care and close contact
with medical doctors, psychologists, and a research
nurse during study participations, which has demon-
strated beneficial effects [99]. Furthermore, the partici-
pation in the trial is considered beneficial for
first-degree relatives to patients with BD, recurrent UD,
or schizophrenia, since enrolment requires objectively
verified cognitive dysfunction, which is known to in-
crease psychiatric illness onset risk in these high-risk
individuals [20]. All participants are reimbursed for
their time and the transport expenses associated with
taking part in the study.
Perspectives
If the findings reveal pro-cognitive efficacy of EPO and
that this is associated with early prefrontal activity
change, this would (1) point to EPO as a candidate com-
pound targeting cognitive dysfunction in somatically
healthy patients with mood disorders and (2) highlight
prefrontal target engagement as a promising biomarker
model for pro-cognitive efficacy. From a methodological
perspective, such findings will be an important step in
future development of cognitive enhancement treat-
ments in neuropsychiatric disorders and preventive
strategies in at-risk populations, which could have sig-
nificant individual and societal implications.
Trial status and dissemination
Participant enrolment was initiated in September 2017
and is expected to continue until autumn 2020.
Follow-up data from the last recruitments will be col-
lected during the winter of 2021. Trial results will be
disseminated in peer-reviewed scientific journals and
presented at scientific conferences and meetings. Author
eligibility is assessed with the Vancouver Convention.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 125 kb)
Abbreviations
ABCR: Action-based cognitive remediation; ANCOVA: Analysis of covariance;
AQoL: Assessment of Quality of Life; BD: Bipolar disorder; BDNF: Brain-derived
neurotrophic factor; BOLD: Blood-oxygen-level dependent; CANTAB: Cambridge
Neuropsychological Test Automated Battery; COBRA: Cognitive Complaints in
Bipolar Disorder Rating Assessment; COMT: Catechol-O-methyltransferase;
DART: Danish Adult Reading Test; dlPFC: Dorsolateral prefrontal cortex;
dmPFC: Dorsomedial prefrontal cortex; dPFC: Dorsal prefrontal cortex;
ECG: Electrocardiography; ECT: Electroconvulsive therapy; EPO: Erythropoietin;
FAST: Functional Assessment Short Test; fMRI: Functional magnetic resonance
imaging; HDRS-17: Hamilton Depression Rating Scale (17-items version);
ISBD: International Society for Bipolar Disorders; ITT: Intention to treat;
mPFC: Medial prefrontal cortex; OTS: One Touch Stocking of Cambridge;
PFC: Prefrontal cortex; PRCA: Pure red cell aplasia; PSQI: Pittsburgh Sleep Quality
Inventory; RAVLT: Rey Auditory Verbal Learning Test; RBANS: Repeatable Battery
for the Assessment of Neuropsychological Status; RCT: Randomized controlled
trial; ROI: Region of interest; RVP: Rapid Visual Processing; SCAN: Schedules for
Clinical Assessment in Neuropsychiatry; SCIP: Screen for Cognitive Impairment
in Psychiatry; SPSS: Statistical Package for Social Sciences; SWM: Short Working
Memory; TMT: Trail Making Test; TRD: Treatment-resistant depression;
UD: Unipolar disorder; UPSA-B: UCSD Performance-Based Skills Assessment-B;
VOI: Volume of interest; WAIS: Wechsler Adult Intelligence Scale;
WHOQOL: World Health Organization Quality of Life; WSAS: Work and
Social Adjustment Scale; YMRS: Young Mania Rating Scale
Acknowledgements
The authors wish to acknowledge the Copenhagen Affective Disorder Clinic,
Psychiatric Center Copenhagen, Copenhagen University Hospital, Rigshospitalet,
Copenhagen, Denmark for assisting with recruitment of participants for this
trial. Julian Macoveanu, Patrick Fisher, and Hanne Lie Kjærstad are
acknowledged for their help with implementation of the fMRI paradigms.
Caroline Vintergaard Ott, Hanne Lie Kjærstad, Klara Coello, and Sharleny
Stanislaus, as well as all private psychiatrist and mental health care centers,
are acknowledged for their assistance in participant recruitment.
Petersen et al. Trials          (2018) 19:611 Page 11 of 14
Funding
The study is supported by the Lundbeck Foundation grant number: R215–
20154121. The Lundbeck Foundation has not been involved in writing the
present manuscript or in the design of the study, nor will the Lundbeck
Foundation be involved in the data collection, analysis, or interpretation of
data.
Availability of data and materials
The datasets generated and/or analyzed during the current study are
available from the corresponding author on reasonable request.
Authors’ contributions
KWM, MV, and LVK conceived of the study. KWM obtained the required
funding for the study. KWM wrote up the study protocol. LVK, MV, and GMK
were involved in optimizing the study protocol. JZP is responsible for
recruitment of participants in collaboration with MV. JZP is responsible for
carrying out the assessments, data collection, data analysis, and interpretation
of the data under supervision of KWM. LVK, MV, IH, MBJ, and HE will contribute
to the interpretation of the clinical findings, while GMK contributes to the
interpretation of the fMRI results. MV and LVK are primarily responsible for
supervising the medical safety in collaboration with IH and MBJ. LSS is involved
in medical examinations and weekly safety monitoring. The named authors will
be involved in the interpretation of the data and will co-author the resulting
articles based on their involvement throughout the study. All authors have read
and approved the present manuscript.
Ethics approval and consent to participate
The study has been approved by the Danish Medicines Agency (EudraCT
number 2016–004023-24), the Ethics Committee in the Capital Region of
Denmark (protocol number H-16043370), and The Danish Data Protection
Agency Capital Region of Denmark (protocol number RHP-2017-020) and has
been retrospectively registered at ClinicalTrials.gov (NCT03315897) https://
clinicaltrials.gov/ct2/show/NCT03315897 on 20th October 2017. Any import-
ant protocol modifications will be reported to the Danish Medicines Agency,
the Ethics Committee in the Capital Region of Denmark, and the Danish Data





JZP, LSS, MBJ, and IH declare no competing interests. KWM has received
consultancy fees from Lundbeck and Allergan. MV discloses consultancy fees
from Lundbeck and Astra Zeneca within the last three years. GMK was
supported by a Center grant from the Innovation Fond, Center for
Experimental Medicine Neuropharmacology (Neuropharm). LVK reports
having been a consultant for Lundbeck, AstraZeneca, and Sunovion
within the last three years. HE holds user patents for EPO in stroke,
schizophrenia, and MS.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Neurocognition and Emotion in Affective Disorder (NEAD) Group,
Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre
Copenhagen, Copenhagen University Hospital, Blegdamsvej 9, DK-2100
Copenhagen, Denmark. 2Department of Psychology, University of
Copenhagen, Øster Farimagsgade 2A, DK-1353 Copenhagen, Denmark.
3Clinical Neuroscience, Max Planck Institute of Experimental Medicine,
Göttingen, Germany. 4DFG Center for Nanoscale Microscopy & Molecular
Physiology of the Brain (CNMPB), Göttingen, Germany. 5Neurobiology
Research Unit and Center for Integrated Molecular Imaging, Rigshospitalet,
Copenhagen, Denmark. 6Faculty of Health and Medical Sciences, University
of Copenhagen, Copenhagen, Denmark.
Received: 2 November 2017 Accepted: 16 October 2018
References
1. Burdick KE, Ketter TA, Goldberg JF, Calabrese JR. Assessing cognitive
function in bipolar disorder: challenges and recommendations for clinical
trial design. J Clin Psychiatry. 2015;76(3):e342–50.
2. Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete
neurocognitive subgroups in fully or partially remitted bipolar disorder:
Associations with functional abilities. J Affect Disord. 2016;205:378–86.
3. Burdick K, Russo M, Frangou S, Mahon K, Braga R, Shanahan M, et al.
Empirical evidence for discrete neurocognitive subgroups in bipolar
disorder: clinical implications. Psychol Med. 2014;44(14):3083–96.
4. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in
euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;
43(10):2017–26.
5. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in
depression: a systematic review and meta-analysis. Psychol Med. 2014;
44(10):2029–40.
6. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA,
Kudlow P, et al. Cognitive deficits and functional outcomes in major
depressive disorder: determinants, substrates, and treatment interventions.
Depress Anxiety. 2013;30(6):515–27.
7. Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV. Cognitive
deficits in the remitted state of unipolar depressive disorder.
Neuropsychology. 2012;26(5):642–51.
8. Baune BT, Malhi GS. A review on the impact of cognitive dysfunction on
social, occupational, and general functional outcomes in bipolar disorder.
Bipolar Disord. 2015;17(Suppl 2):41–55.
9. Bourne C, Aydemir Ö, Balanzá-Martínez V, Bora E, Brissos S, Cavanagh JTO,
et al. Neuropsychological testing of cognitive impairment in euthymic
bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr
Scand. 2013;128(3):149–62.
10. Bortolato B, Miskowiak KW, Köhler CA, Vieta E, Carvalho AF. Cognitive
dysfunction in bipolar disorder and schizophrenia: a systematic review of
meta-analyses. Neuropsychiatr Dis Treat. 2015;11:3111–25.
11. Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable
employment outcomes among individuals with bipolar disorder. Bipolar
Disord. 2014;16(3):217–29.
12. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and
disability in major depressive disorder. Psychiatry Res. 2006;145(1):39–48.
13. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B, on behalf of
the Csg, et al. The economic cost of brain disorders in Europe. Eur J Neurol.
2012;19(1):155–62.
14. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness–
1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30(5):213–9.
15. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder:
A meta-analysis of neuropsychological deficits in euthymic patients and
their first-degree relatives. J Affect Disord. 2009;113(1):1–20.
16. Porter RJ, Robinson LJ, Malhi GS, Gallagher P. The neurocognitive profile of
mood disorders – a review of the evidence and methodological issues.
Bipolar Disord. 2015;17:21–40.
17. Christensen MV, Kyvik KO, Kessing LV. Cognitive function in unaffected
twins discordant for affective disorder. Psychol Med. 2006;36(8):1119–29.
18. Keshavan MS, Kulkarni S, Bhojraj T, Francis A, Diwadkar V, Montrose DM,
et al. Premorbid cognitive deficits in young relatives of schizophrenia
patients. Front Hum Neurosci. 2010;3:62.
19. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits
in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res.
2004;71(2–3):285–95.
20. Vinberg M, Miskowiak KW, Kessing LV. Impairment of executive function
and attention predicts onset of affective disorder in healthy high-risk twins.
J Clin Psychiatry. 2013;74(8):e747–53.
21. Iosifescu DV. The relation between mood, cognition and psychosocial
functioning in psychiatric disorders. Eur Neuropsychopharmacol. 2012;
22(Suppl 3):S499–504.
22. Miskowiak KW, Carvalho AF, Vieta E, Kessing LV. Cognitive enhancement
treatments for bipolar disorder: A systematic review and methodological
recommendations. Eur Neuropsychopharmacol. 2016;26(10):1541–61.
23. Nathan PJ, Phan KL, Harmer CJ, Mehta MA, Bullmore ET. Increasing
pharmacological knowledge about human neurological and psychiatric
Petersen et al. Trials          (2018) 19:611 Page 12 of 14
disorders through functional neuroimaging and its application in drug
discovery. Curr Opin Pharmacol. 2014;14:54–61.
24. Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, et al.
Cognitive dysfunction in psychiatric disorders: characteristics, causes and
the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141–68.
25. Dietsche B, Backes H, Stratmann M, Konrad C, Kircher T, Krug A. Altered
neural function during episodic memory encoding and retrieval in major
depression. Hum Brain Mapp. 2014;35(9):4293–302.
26. Frangou S, Kington J, Raymont V, Shergill SS. Examining ventral and dorsal
prefrontal function in bipolar disorder: a functional magnetic resonance
imaging study. Eur Psychiatry. 2008;23(4):300–8.
27. Hamilton LS, Altshuler LL, Townsend J, Bookheimer SY, Phillips OR, Fischer J,
et al. Alterations in functional activation in euthymic bipolar disorder and
schizophrenia during a working memory task. Hum Brain Mapp. 2009;30(12):
3958–69.
28. Harvey P-O, Fossati P, Pochon J-B, Levy R, LeBastard G, Lehéricy S, et al.
Cognitive control and brain resources in major depression: An fMRI study
using the n-back task. NeuroImage. 2005;26(3):860–9.
29. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41
functional neuroimaging studies of executive function in schizophrenia.
Arch Gen Psychiatry. 2009;66(8):811–22.
30. Townsend J, Bookheimer SY, Foland-Ross LC, Sugar CA, Altshuler LL. fMRI
abnormalities in dorsolateral prefrontal cortex during a working memory
task in manic, euthymic and depressed bipolar subjects. Psychiatry Res.
2010;182(1):22–9.
31. Piguet C, Fodoulian L, Aubry J-M, Vuilleumier P, Houenou J. Bipolar disorder:
Functional neuroimaging markers in relatives. Neurosci Biobehav Rev. 2015;
57:284–96.
32. Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC.
Prefrontal Activation Deficits During Episodic Memory in Schizophrenia. Am
J Psychiatry. 2009;166(8):863–74.
33. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as
neuroprotective and neuroregenerative treatment strategy: Comprehensive
overview of 12 years of preclinical and clinical research. Best Pract Res Clin
Anaesthesiol. 2010;24(4):573–94.
34. Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D, et al. Treating
patients with schizophrenia deficit with erythropoietin? Psychiatry Clin
Neurosci. 2012;66(5):375–82.
35. Kastner A, Grube S, El-Kordi A, Stepniak B, Friedrichs H, Sargin D, et al.
Common variants of the genes encoding erythropoietin and its
receptor modulate cognitive performance in schizophrenia. Mol Med.
2012;18:1029–40.
36. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV.
Erythropoietin: a candidate treatment for mood symptoms and memory
dysfunction in depression. Psychopharmacology. 2012;219(3):687–98.
37. Siren AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of
erythropoietin and its structural or functional variants in the nervous
system. Neurotherapeutics. 2009;6(1):108–27.
38. Sackeim HA. The definition and meaning of treatment-resistant depression.
J Clin Psychiatry. 2001;62(suppl 16):10–7.
39. Miskowiak KW, Ehrenreich H, Christensen EM, Kessing LV, Vinberg M.
Recombinant human erythropoietin to target cognitive dysfunction in
bipolar disorder: a double-blind, randomized, placebo-controlled phase 2
trial. J Clin Psychiatry. 2014;75(12):1347–55.
40. Miskowiak KW, Vinberg M, Christensen EM, Bukh JD, Harmer CJ, Ehrenreich
H, et al. Recombinant human erythropoietin for treating treatment-resistant
depression: a double-blind, randomized, placebo-controlled phase 2 trial.
Neuropsychopharmacology. 2014;39(6):1399–408.
41. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al.
Exploring recombinant human erythropoietin in chronic progressive
multiple sclerosis. Brain. 2007;130(Pt 10):2577–88.
42. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S,
et al. Improvement of cognitive functions in chronic schizophrenic patients
by recombinant human erythropoietin. Mol Psychiatry. 2007;12(2):206–20.
43. Jang W, Park J, Shin KJ, Kim JS, Kim JS, Youn J, et al. Safety and efficacy of
recombinant human erythropoietin treatment of non-motor symptoms in
Parkinson’s disease. J Neurol Sci. 2014;337(1–2):47–54.
44. Macoveanu J, Miskowiak K, Kessing LV, Vinberg M, Siebner HR. Healthy co-
twins of patients with affective disorders show reduced risk-related
activation of the insula during a monetary gambling task. J Psychiatry
Neurosci. 2016;41(1):38–47.
45. Miskowiak KW, Vinberg M, Glerup L, Paulson OB, Knudsen GM, Ehrenreich H,
et al. Neural correlates of improved executive function following erythropoietin
treatment in mood disorders. Psychol Med. 2016;46(8):1679–91.
46. Miskowiak K, O'Sullivan U, Harmer CJ. Erythropoietin enhances hippocampal
response during memory retrieval in humans. J Neurosci. 2007;27(11):2788–92.
47. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ, et al.
Effects of erythropoietin on emotional processing biases in patients with
major depression: an exploratory fMRI study. Psychopharmacology. 2009;
207(1):133–42.
48. Ott CV, Vinberg M, Kessing LV, Miskowiak KW. The effect of erythropoietin
on cognition in affective disorders–Associations with baseline deficits and
change in subjective cognitive complaints. Eur Neuropsychopharmacol.
2016;26(8):1264–73.
49. Miskowiak KW, Rush AJ, Gerds TA, Vinberg M, Kessing LV. Targeting
treatments to improve cognitive function in mood disorder: suggestions
from trials using erythropoietin. J Clin Psychiatry. 2016;77(12):e1639-46.
50. Miskowiak KW, Burdick KE, Martinez-Aran A, Bonnin CM, Bowie CR, Carvalho
AF, McIntyre RS. Methodological recommendations for cognition trials in
bipolar disorder by the International Society for Bipolar Disorders Targeting
Cognition Task Force. Bipolar Disord. 2017;19(8):614-26.
51. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry.
1960;23:56–62.
52. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania:
reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.
53. Jensen JH, Stottrup MM, Nayberg E, Knorr U, Ullum H, Purdon SE, et al.
Optimising screening for cognitive dysfunction in bipolar disorder:
Validation and evaluation of objective and subjective tools. J Affect Disord.
2015;187:10–9.
54. Purdon SE. The Screen for Cognitive Impairment in Psychiatry:
Administration and Psychometric Properties. Edmonton: PNL, Inc.; 2005.
55. Ott CV, Bjertrup AJ, Jensen JH, Ullum H, Sjaelland R, Purdon SE, et al. Screening
for cognitive dysfunction in unipolar depression: Validation and evaluation of
objective and subjective tools. J Affect Disord. 2016;190:607–15.
56. Crawford JR, Besson JAO, Parker DM, Sutherland KM, Keen PL. Estimation of
premorbid intellectual status in depression. Br J Clin Psychol. 1987;26(4):313–4.
57. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN.
Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry.
1990;47(6):589–93.
58. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM,
Macoveanu J, et al. Effects of erythropoietin on depressive symptoms and
neurocognitive deficits in depression and bipolar disorder. Trials. 2010;11:97.
59. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, et al.
Erythropoietin: a candidate compound for neuroprotection in
schizophrenia. Mol Psychiatry. 2004;9(1):42–54.
60. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh
sleep quality index: A new instrument for psychiatric practice and research.
Psychiatry Res. 1989;28(2):193–213.
61. Miskowiak K, Inkster B, O'Sullivan U, Selvaraj S, Goodwin GM, Harmer CJ.
Differential effects of erythropoietin on neural and cognitive measures of
executive function 3 and 7 days post-administration. Exp Brain Res. 2008;
184(3):313–21.
62. Schmidt M. Rey auditory verbal learning test: A handbook (p. 1996). Los
Angeles: Western Psychological Services; 1996.
63. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS): preliminary clinical
validity. J Clin Exp Neuropsychol. 1998;20(3):310–9.
64. Borkowski J, Benton AL, Spreen O. Word fluency and brain damage.
Neuropsychologia. 1967;5:135–40.
65. Wechsler D. Wechsler Adult Intelligence Scale, 3rd ed. (WAIS-III). San
Antonio: The Psychological Corporation; 1997.
66. Army Individual Test Battery. Manual of directions and scoring. Washington,
DC: War Department, Adjutant General’s Office; 1944.
67. Rosa AR, Sanchez-Moreno J, Martinez-Aran A, Salamero M, Torrent C,
Reinares M, et al. Validity and reliability of the Functioning Assessment Short
Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.
68. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life
(AQoL) instrument: a psychometric measure of Health-Related Quality of
Life. Qual Life Res. 1999;8(3):209–24.
69. Rosa AR, Mercadé C, Sánchez-Moreno J, Solé B, Mar Bonnin CD, Torrent C,
et al. Validity and reliability of a rating scale on subjective cognitive deficits
in bipolar disorder (COBRA). J Affect Disord. 2013;150(1):29–36.
Petersen et al. Trials          (2018) 19:611 Page 13 of 14
70. Sheehan DV. The Anxiety Disease. New York: Charles Scribner’s Sons; 1983.
71. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-
Based Skills Assessment: development of a new measure of everyday
functioning for severely mentally ill adults. Schizophr Bull. 2001;27(2):235–45.
72. Vesterager L, Christensen TO, Olsen BB, Krarup G, Forchhammer HB, Melau
M, et al. Cognitive training plus a comprehensive psychosocial programme
(OPUS) versus the comprehensive psychosocial programme alone for
patients with first-episode schizophrenia (the NEUROCOM trial): a study
protocol for a centrally randomised, observer-blinded multi-centre clinical
trial. Trials. 2011;12:35.
73. The WHOQOL Group. The Development of the World Health Organization
Quality of Life Assessment Instrument (the WHOQOL). In: Orley J, Kuyken W,
editors. Berlin: Quality of Life Assessment: International Perspectives.
Springer; 1994.
74. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment
Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;
180(5):461–4.
75. Sanders B, Becker-Lausen E. The measurement of psychological
maltreatment: Early data on the child abuse and trauma scale. Child Abuse
Negl. 1995;19(3):315–23.
76. Chang HH, Lee IH, Gean PW, Lee S-Y, Chi MH, Yang YK, et al. Treatment
response and cognitive impairment in major depression: Association with
C-reactive protein. Brain Behav Immun. 2012;26(1):90–5.
77. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R.
Elevated C-reactive protein and cognitive deficits in individuals with bipolar
disorder. J Affect Disord. 2013;150(2):456–9.
78. Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E. Interleukin-6 and
verbal memory in recurrent major depressive disorder. Neuro Endocrinol
Lett. 2011;32(4):540–4.
79. Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS.
Inflammation as a neurobiological substrate of cognitive impairment in
bipolar disorder: Evidence, pathophysiology and treatment implications. J
Affect Disord. 2015;188:149–59.
80. Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik Mehmet S. Assessment
of cytokine levels and hs-CRP in bipolar I disorder before and after
treatment. Psychiatry Res. 2015;228(3):386–92.
81. Vinberg M, Miskowiak K, Hoejman P, Pedersen M, Kessing LV. The effect of
recombinant erythropoietin on plasma brain derived neurotrophic factor
levels in patients with affective disorders: a randomised controlled study.
PLoS One. 2015;10(5):e0127629.
82. Vinberg M, Weikop P, Olsen NV, Kessing LV, Miskowiak K. Effect of
recombinant erythropoietin on inflammatory markers in patients with
affective disorders: A randomised controlled study. Brain Behav Immun.
2016;57:53–7.
83. Vinberg M, Hojman P, Pedersen BK, Kessing LV, Miskowiak KW. Effects of
erythropoietin on body composition and fat-glucose metabolism in patients
with affective disorders. Acta Neuropsychiatr. 2018;1–8. https://doi.org/10.
1017/neu.2018.16.
84. Seeberg I, Kjaerstad HL, Miskowiak KW. Neural and behavioral predictors of
treatment efficacy on mood symptoms and cognition in mood disorders: a
systematic review. Front Psychiatry. 2018;9:337. https://doi.org/10.3389/fpsyt.
2018.00337.
85. Kessing LV, Munkholm K, Faurholt-Jepsen M, Miskowiak KW, Nielsen LB,
Frikke-Schmidt R, et al. The Bipolar Illness Onset study: research protocol for
the BIO cohort study. BMJ Open. 2017;7(6):e015462.
86. Vinberg M, Miskowiak K, Kessing LV. Risk markers for affective disorder, a
seven-years follow up study of a twin cohort at low and high risk for
affective disorder. J Psychiatr Res. 2013;47(5):565–71.
87. Gualtieri CT, Morgan DW. The frequency of cognitive impairment in patients
with anxiety, depression, and bipolar disorder: an unaccounted source of
variance in clinical trials. J Clin Psychiatry. 2008;69(7):1122–30.
88. FDA Critical Path Initiative. http://www.fda.gov/oc/initiatives/criticalpath /
http://www.nimh.nih.gov/about/director/2014/a-new-approach-to-clinical-
trials.shtml.
89. Bowie CR, Grossman M, Gupta M, Holshausen K, Best MW. Action-based
cognitive remediation for individuals with serious mental illnesses: Effects of
real-world simulations and goal setting on functional and vocational
outcomes. Psychiatr Rehabil J. 2017;40(1):53.
90. Vieta E. The influence of medications on neurocognition in bipolar disorder.
Acta Psychiatr Scand. 2009;120(6):414–5.
91. Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, et al.
Treatment of cancer-related anemia with epoetin alfa: a review. Cancer
Treat Rev. 2004;30(6):563–75.
92. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg
K, et al. Recombinant human erythropoietin in the treatment of acute
ischemic stroke. Stroke. 2009;40(12):e647–56.
93. Lund A, Lundby C, Olsen NV. High-dose erythropoietin for tissue protection.
Eur J Clin Investig. 2014;44(12):1230–8.
94. Debeljak N, Solar P, Sytkowski AJ. Erythropoietin and cancer: the unintended
consequences of anemia correction. Front Immunol. 2014;5:563.
95. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW,
et al. Epoetin-associated pure red cell aplasia: past, present, and future
considerations. Transfusion. 2008;48(8):1754–62.
96. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU,
et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney
disease. N Engl J Med. 2009;361(21):2019–32.
97. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin
concentrations in anaemic patients with chronic kidney disease treated with
erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381–8.
98. Miskowiak KW, Ott CV, Petersen JZ, Kessing LV. Systematic review of
randomized controlled trials of candidate treatments for cognitive
impairment in depression and methodological challenges in the field. Eur
Neuropsychopharmacol. 2016;26(12):1845–67.
99. Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments
on antidepressant and placebo response rates in antidepressant efficacy
trials: meta-analysis. Br J Psychiatry. 2007;190:287–92.
Petersen et al. Trials          (2018) 19:611 Page 14 of 14
